On Thursday September 30th, INNODIA had an own session at EASD2021, where Prof. Thomas Danne and Prof. Søren Brunak presented and explained all different ongoing studies in the project, as well as their specific work area.
A few topics that were put in the spotlight were;
The 4 ongoing clinical trials for newly diagnosed type 1 diabetes patients
Vera+ as an additional sub-trial to see whether or not the protective effect of the beta-cell is in place
The importance of a Master Protocol, individualization and standardization in intervention studies
INNODIA seeing three "flavors" of T1D when considering c-peptide levels
